Monovisc FDA Approval History
FDA Approved: Yes (First approved February 24, 2014)
Brand name: Monovisc
Generic name: sodium hyaluronate
Dosage form: Injection
Company: Anika Therapeutics, Inc.
Treatment for: Osteoarthritis
Monovisc (sodium hyaluronate) is a viscoelastic supplement indicated for the treatment of pain associated with osteoarthritis of the knee.
Development timeline for Monovisc
| Date | Article |
|---|---|
| Feb 27, 2014 | Approval FDA Approves Monovisc, a New Single Injection Treatment for Pain Due to Osteoarthritis of the Knee |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.